Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 5Hepatitis B, Chronic 3Hepatitis B 3Lymphoma 2Virus Diseases 1Recurrence 1Paraparesis, Tropical Spastic 1Neuritis 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Leukemia-Lymphoma, Adult T-Cell 1Infections 1HTLV-I Infections 1Fibrosis 1Epstein-Barr Virus Infections 1Burkitt Lymphoma 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 9Ciprofloxacin 7Voriconazole 5Caspofungin 4Amoxicillin-Potassium Clavulanate Combination 4gamma-Globulins 3Vancomycin 3Fluconazole 3Filgrastim 3Daptomycin 3Antibiotic Prophylaxis 3plerixafor 2liposomal amphotericin B 2Trimethoprim 2Therapeutics 2Sulfamethoxazole 2Saline Solution 2Ribavirin 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Pentetic Acid 2Moxifloxacin 2Melphalan 2Levofloxacin 2Itraconazole 2Immunoglobulins, Intravenous 2Granulocyte Colony-Stimulating Factor 2Ethanol 2Cyclophosphamide 2Cefazolin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Infections × Tenofovir × Clear all
NCT07133776 2025-08-21

Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.

The Affiliated Hospital of Xuzhou Medical University

Phase 1/2 Not yet recruiting
30 enrolled

Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡